<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04208958</url>
  </required_header>
  <id_info>
    <org_study_id>VE800-001</org_study_id>
    <nct_id>NCT04208958</nct_id>
  </id_info>
  <brief_title>Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer</brief_title>
  <acronym>Consortium-IO</acronym>
  <official_title>Phase 1 Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vedanta Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vedanta Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of VE800 in combination with Nivolumab in
      patients with selected types of advanced or metastatic cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CONSORTIUM-IO is a first-in-human multicenter, open-label study, where it's main objectives
      will evaluate:

        -  Safety and tolerability of VE800 in combination with Nivolumab

        -  Efficacy as measured by a total of overall response rate.

      The study will enroll approximately 111 patients with melanoma, patients with
      gastric/gastroesophageal junction (GEJ) adenocarcinoma, and patients with
      microsatellite-stable (MSS) colorectal cancer (CRC).

      Nivolumab is an already approved by the FDA (the U.S. Food and Drug Administration), however,
      it is not approved for the study cancer indications. VE800 is the investigational product and
      alive VE800 bacterial consortium were designed to elicit an immune response.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 23, 2020</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This study design will help determine how safe and effective the study drug, VE800, in combination with nivolumab in patients with advanced/metastatic cancer.
The following cohorts of patients with advanced/metastatic cancer will be enrolled:
Melanoma
Gastric/gastroesophageal junction (GEJ) adenocarcinoma
Colorectal cancer (microsatellite-stable) (CRC-MSS)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of VE800 in combination with nivolumab: incidence of adverse events</measure>
    <time_frame>From the first dose to 100 days after the last dose</time_frame>
    <description>Will be measured in terms of incidence of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate clinical activity</measure>
    <time_frame>From the first dose to 100 days after the last dose</time_frame>
    <description>Will be measured as objective response rate (ORR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>From the first dose to 100 days after the last dose</time_frame>
    <description>Evaluation of clinical benefit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response</measure>
    <time_frame>From the first dose to 100 days after the last dose</time_frame>
    <description>Evaluation of clinical benefit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>From the first dose to 100 days after the last dose</time_frame>
    <description>Evaluation of clinical benefit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>From the first dose to 100 days after the last dose</time_frame>
    <description>Evaluation of clinical benefit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From the first dose to 100 days after the last dose</time_frame>
    <description>Evaluation of clinical benefit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of VE800 bacterial strain colonization in stool</measure>
    <time_frame>From the first dose to 100 days after the last dose</time_frame>
    <description>Measured by pharmacokinetics (PK) of VE800</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of VE800 bacterial strain colonization in stool</measure>
    <time_frame>From the first dose to 100 days after the last dose</time_frame>
    <description>Measured by pharmacokinetics (PK) of VE800colonization in stool</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of VE800 bacterial strain colonization in stool</measure>
    <time_frame>From the first dose to 100 days after the last dose</time_frame>
    <description>Measured by pharmacokinetics (PK) of VE800colonization in stool</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">111</enrollment>
  <condition>Metastatic Cancer</condition>
  <condition>Melanoma</condition>
  <condition>Gastric Cancer</condition>
  <condition>Gastroesophageal Junction Adenocarcinoma</condition>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>VE800 combination treatment with Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 5 days of oral vancomycin, followed by daily VE800 in combination with Nivolumab every 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VE800</intervention_name>
    <description>VE800 is an orally administered (PO) live biotherapeutic product (LBP) consisting of 11 distinct nonpathogenic, nontoxigenic, commensal bacterial strains manufactured under GMP conditions. These strains were selected for their ability to induce an immune response.</description>
    <arm_group_label>VE800 combination treatment with Nivolumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab is an approved medication that blocks antibodies for certain types of cancer.</description>
    <arm_group_label>VE800 combination treatment with Nivolumab</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin Oral Capsule</intervention_name>
    <description>Vancomycin is an antibiotic used to treat or prevent infection.</description>
    <arm_group_label>VE800 combination treatment with Nivolumab</arm_group_label>
    <other_name>Vancoccin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Partial Inclusion Criteria:

          -  Patients with advanced or metastatic cancer who have received no more than 3 lines of
             prior systemic therapy for advanced/metastatic disease.

          -  Histologically diagnosed advanced (unresectable) or metastatic cancer with at least
             one measurable lesion as per RECIST 1.1

          -  Tumor lesions amenable for biopsy, if deemed safe by the investigator

          -  Toxicity from prior cancer therapy should resolve to CTCAE Grade â‰¤ 1 (excluding
             alopecia and neuropathy, where up to Grade 2 residual is allowed)

        Partial Exclusion Criteria:

          -  Prior treatment with immune checkpoint inhibitor (iCPI) (Note: this criterion does not
             apply to patients with melanoma)

          -  Receipt of any conventional or investigational systemic anti-cancer therapy within 26
             days prior to the start of study treatment

          -  Concurrent chemotherapy, immunotherapy, biologic, or hormonal anti-cancer therapy.
             Agents such as bisphosphonates or denosumab are acceptable as prophylaxis for bone
             metastasis.

          -  Patients must not have received a transfusion (platelets or red blood cells) within 4
             weeks of the first dose of study treatment

          -  Patients with an active, known or suspected autoimmune disease. Patients with type I
             diabetes mellitus, hypothyroidism only requiring hormone replacement, skin not
             requiring systemic treatment are permitted to enroll.

          -  Patients with known active hepatitis (e.g., hepatitis B or C) NOTE: Patients with
             previously treated hepatitis B or C are permitted to enroll if there is evidence of
             documented resolution of infection.

          -  Received a fecal transplant, spore or other preparation of fecal material, isolated
             bacterial products, genetically modified bacteria, or VE800
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lorraine Hughes</last_name>
    <phone>857-706-1427</phone>
    <email>ConsortiumIO-ctinquiries@vedantabio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Kim</last_name>
    <phone>857-706-1427</phone>
    <email>ConsortiumIO-ctinquiries@vedantabio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Angeles Clinic and Research Institute - West Los Angeles Office</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Berroya</last_name>
      <phone>310-231-2111</phone>
      <email>hberroya@theangelesclinic.org</email>
    </contact>
    <investigator>
      <last_name>Omid Hamid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Olsen</last_name>
      <phone>941-377-9993</phone>
      <phone_ext>7247</phone_ext>
      <email>nolsen@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Judy Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Younger, RN</last_name>
      <phone>317-274-0951</phone>
      <email>anefoste@iupui.edu</email>
    </contact>
    <investigator>
      <last_name>Anita Turk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chelsea McCabe</last_name>
      <phone>551-996-4725</phone>
      <email>Chelsea.McCabe@hackensackmeridian.org</email>
    </contact>
    <investigator>
      <last_name>Martin Gutierrez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aaron Vannatter</last_name>
      <phone>412-623-2943</phone>
      <email>vannattera@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Diwakar Davar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Oncology - First Hill</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neil Bailey</last_name>
      <phone>206-386-2310</phone>
      <email>neil.bailey@swedish.org</email>
    </contact>
    <investigator>
      <last_name>Philip Gold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 16, 2019</study_first_submitted>
  <study_first_submitted_qc>December 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2019</study_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic Cancer</keyword>
  <keyword>VE800</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>Opdivo</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Gastric Cancer</keyword>
  <keyword>Gastroesophageal Junction Adenocarcinoma</keyword>
  <keyword>GEJ Adenocarcinoma</keyword>
  <keyword>Colorectal Cancer</keyword>
  <keyword>CRC-MSS</keyword>
  <keyword>Vedanta</keyword>
  <keyword>BMS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

